 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by William Robinson and Kasey Couts.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.107 |
|
|
|
-
Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA. ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 01; 17(1):222-231.
Score: 0.638
-
Borgers JSW, Tobin RP, Torphy RJ, Vorwald VM, Van Gulick RJ, Amato CM, Cogswell DT, Chimed TS, Couts KL, Van Bokhoven A, Raeburn CD, Lewis KD, Wisell J, McCarter MD, Mushtaq RR, Robinson WA. Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors. J Natl Compr Canc Netw. 2021 Aug 04.
Score: 0.207
-
Holman BN, Van Gulick RJ, Amato CM, MacBeth ML, Davies KD, Aisner DL, Robinson WA, Couts KL. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Res. 2020 12; 30(6):562-573.
Score: 0.198
-
Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL. BRAF fusions identified in melanomas have variable treatment responses and phenotypes. Oncogene. 2019 02; 38(8):1296-1308.
Score: 0.170
-
Couts KL, McCoach CE, Murphy D, Christiansen J, Turner J, Lewis KD, Robinson WA, Doebele RC. Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to Entrectinib. JCO Precis Oncol. 2017 Nov; 1:1-7.
Score: 0.160
-
Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017 06; 27(3):189-199.
Score: 0.155
-
Turner JA, Fredrickson MA, D'Antonio M, Katsnelson E, MacBeth M, Van Gulick R, Chimed TS, McCarter M, D'Alessandro A, Robinson WA, Couts KL, Pelanda R, Klarquist J, Tobin RP, Torres RM. Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity. Nat Commun. 2023 06 03; 14(1):3214.
Score: 0.059
-
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
Score: 0.058
-
Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. Cancer Discov. 2022 12 02; 12(12):2856-2879.
Score: 0.057
-
Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. JAMA Netw Open. 2022 12 01; 5(12):e2246400.
Score: 0.057
-
Turner JA, Paton EL, Van Gulick R, Stefanoni D, Cendali F, Reisz J, Tobin RP, McCarter M, D'Alessandro A, Torres RM, Robinson WA, Couts KL, Schlaepfer IR. BRAF Modulates Lipid Use and Accumulation. Cancers (Basel). 2022 Apr 23; 14(9).
Score: 0.054
-
Vorwald VM, Davis DM, Van Gulick RJ, Torphy RJ, Borgers JS, Klarquist J, Couts KL, Amato CM, Cogswell DT, Fujita M, Castleman MJ, Davis T, Lozupone C, Medina TM, Robinson WA, Gapin L, McCarter MD, Tobin RP. Circulating CD8+ mucosal-associated invariant T cells correlate with improved treatment responses and overall survival in anti-PD-1-treated melanoma patients. Clin Transl Immunology. 2022; 11(1):e1367.
Score: 0.053
-
Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. J Invest Dermatol. 2022 07; 142(7):1912-1922.e7.
Score: 0.053
-
Dart CR, Mukherjee N, Amato CM, Goulding A, MacBeth M, Van Gulick R, Couts KL, Lambert JR, Norris DA, Robinson WA, Shellman YG. A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. Pharmaceuticals (Basel). 2021 Jul 30; 14(8).
Score: 0.052
-
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 06 08; 11(6):443.
Score: 0.048
-
Tobin RP, Jordan KR, Kapoor P, Spongberg E, Davis D, Vorwald VM, Couts KL, Gao D, Smith DE, Borgers JSW, Robinson S, Amato C, Gonzalez R, Lewis KD, Robinson WA, Borges VF, McCarter MD. IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. Front Oncol. 2019; 9:1223.
Score: 0.046
-
Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, Amato CM, Couts KL, Bemis JGT, Turner JA, Norris DA, Shellman YG. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis. 2018 09 05; 9(9):907.
Score: 0.042
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|